Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health ...

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

Wegovy (semaglutide) is approved by the U.S. Food and Drug Administration (FDA) for weight loss and weight management in ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector . New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via a ...

The three AGA mouse model groups were treated separately for 18 days as follows: Mock (subcutaneous injection ... μL PBS was injected subcutaneously into five dorsal skin sites (20 μL per injection ...

BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on ...

Eden, the leading health platform connecting individuals with independent licensed providers and pharmacies focused on ...

Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...